Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070096735> ?p ?o ?g. }
- W2070096735 endingPage "235" @default.
- W2070096735 startingPage "222" @default.
- W2070096735 abstract "A new approach to functional tumor imaging and deep interstitial penetration of therapeutic agents is to target the upregulated transport activities of neovascular endothelium. Agents are formulated with the anionic glycosaminoglycan, 435-type dermatan sulfate (DS 435, 22.2 kDa), chemically enriched for oligosaccharide sequences that confer high heparin cofactor II binding and correlate with high tumor uptake. A magnetic resonance (MR) imaging agent is prepared as self-assembling, 5-nm nanoparticles of Fe(+3):deferoxamine (Fe:Df) bound by strong ion pairing to DS, which forms the outer molecular surface (Zeta potential -39 mV). On intravenous (i.v.) injection, Fe:Df-DS rapidly (<7 min) and selectively targets and transports at high capacity across the neovascular endothelium of large (2-cm) Dunning prostate R3327 AT1 rat tumors; releases from the abluminal surface, due to reversible binding of its multivalent, low-affinity (K(d) 10(-4) to 10(-5)) oligosaccharide ligands; and progressively penetrates the interstitium from its initial site of high uptake in the well-perfused outer tumor rim, into the poorly perfused central subregion. By gamma camera imaging of (67)Ga:Df-DS, the agent avoids normal site uptake and clears through the kidneys with a t(1/2) of 18 min. A therapeutic formulation of DS-doxorubicin (DS-dox) is prepared by aqueous high-pressure homogenization of the drug and DS 435, which produces 11-nm nanoparticles of doxorubicin cores coated with DS (Zeta potential -39 mV) that are stable to lyophilization. Microscopic analysis of tumor sections 3 h after i.v. injection shows much higher overall tumor fluorescence and deeper matrix penetration for DS-dox than conventional doxorubicin (dox): >75 vs. <25 microm between the nearest microvessels. DS-dox also results in enhanced tumor-cell internalization and nuclear localization of the drug. Therapeutic efficacies in established (250 +/- 15 mg) MX-1 human breast tumor xenografts at maximum tolerated doses (MTDs) are (control vehicle, dox, dox-DS) (a) median days to 7-fold tumor growth: 8.3, 25.6 (p = 0.0007), 43.2 (p = 0.0001); (b) complete 90-day tumor regressions: 0/10, 0/10, 4/10. These results demonstrate the potential to develop a novel class of carbohydrate-targeted neovascular transport agents for sensitive, high-resolution (100-microm) MR imaging and improved treatment of larger sized human tumor metastases." @default.
- W2070096735 created "2016-06-24" @default.
- W2070096735 creator A5008689600 @default.
- W2070096735 creator A5024895063 @default.
- W2070096735 creator A5038314892 @default.
- W2070096735 creator A5042028269 @default.
- W2070096735 creator A5054941710 @default.
- W2070096735 creator A5083161716 @default.
- W2070096735 creator A5083825023 @default.
- W2070096735 creator A5086267158 @default.
- W2070096735 creator A5090381580 @default.
- W2070096735 date "2005-12-01" @default.
- W2070096735 modified "2023-10-14" @default.
- W2070096735 title "Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy" @default.
- W2070096735 cites W1480795950 @default.
- W2070096735 cites W1593844282 @default.
- W2070096735 cites W1595121326 @default.
- W2070096735 cites W1622358858 @default.
- W2070096735 cites W1716305818 @default.
- W2070096735 cites W1964935114 @default.
- W2070096735 cites W1967757749 @default.
- W2070096735 cites W1978744203 @default.
- W2070096735 cites W1978815390 @default.
- W2070096735 cites W1985175309 @default.
- W2070096735 cites W1989657857 @default.
- W2070096735 cites W1995397049 @default.
- W2070096735 cites W2003864591 @default.
- W2070096735 cites W2005768609 @default.
- W2070096735 cites W2007086823 @default.
- W2070096735 cites W2008983317 @default.
- W2070096735 cites W2014677661 @default.
- W2070096735 cites W2016485434 @default.
- W2070096735 cites W2016836695 @default.
- W2070096735 cites W2023027189 @default.
- W2070096735 cites W2029528711 @default.
- W2070096735 cites W2036477188 @default.
- W2070096735 cites W2041234923 @default.
- W2070096735 cites W2059864970 @default.
- W2070096735 cites W2064973401 @default.
- W2070096735 cites W2078468203 @default.
- W2070096735 cites W2123774138 @default.
- W2070096735 cites W2126249291 @default.
- W2070096735 cites W2149601493 @default.
- W2070096735 cites W2157164941 @default.
- W2070096735 cites W2164313067 @default.
- W2070096735 cites W2186157682 @default.
- W2070096735 cites W4244817735 @default.
- W2070096735 cites W46774609 @default.
- W2070096735 cites W73960470 @default.
- W2070096735 cites W9128049 @default.
- W2070096735 doi "https://doi.org/10.1016/j.jconrel.2005.09.022" @default.
- W2070096735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16290245" @default.
- W2070096735 hasPublicationYear "2005" @default.
- W2070096735 type Work @default.
- W2070096735 sameAs 2070096735 @default.
- W2070096735 citedByCount "31" @default.
- W2070096735 countsByYear W20700967352012 @default.
- W2070096735 countsByYear W20700967352013 @default.
- W2070096735 countsByYear W20700967352014 @default.
- W2070096735 countsByYear W20700967352015 @default.
- W2070096735 countsByYear W20700967352016 @default.
- W2070096735 countsByYear W20700967352017 @default.
- W2070096735 countsByYear W20700967352020 @default.
- W2070096735 countsByYear W20700967352021 @default.
- W2070096735 countsByYear W20700967352023 @default.
- W2070096735 crossrefType "journal-article" @default.
- W2070096735 hasAuthorship W2070096735A5008689600 @default.
- W2070096735 hasAuthorship W2070096735A5024895063 @default.
- W2070096735 hasAuthorship W2070096735A5038314892 @default.
- W2070096735 hasAuthorship W2070096735A5042028269 @default.
- W2070096735 hasAuthorship W2070096735A5054941710 @default.
- W2070096735 hasAuthorship W2070096735A5083161716 @default.
- W2070096735 hasAuthorship W2070096735A5083825023 @default.
- W2070096735 hasAuthorship W2070096735A5086267158 @default.
- W2070096735 hasAuthorship W2070096735A5090381580 @default.
- W2070096735 hasConcept C106847996 @default.
- W2070096735 hasConcept C12554922 @default.
- W2070096735 hasConcept C127413603 @default.
- W2070096735 hasConcept C141071460 @default.
- W2070096735 hasConcept C155672457 @default.
- W2070096735 hasConcept C171250308 @default.
- W2070096735 hasConcept C178790620 @default.
- W2070096735 hasConcept C18150654 @default.
- W2070096735 hasConcept C185154212 @default.
- W2070096735 hasConcept C185592680 @default.
- W2070096735 hasConcept C192562407 @default.
- W2070096735 hasConcept C202751555 @default.
- W2070096735 hasConcept C2776694085 @default.
- W2070096735 hasConcept C2777557582 @default.
- W2070096735 hasConcept C2777807558 @default.
- W2070096735 hasConcept C2778041096 @default.
- W2070096735 hasConcept C2778066728 @default.
- W2070096735 hasConcept C2779820397 @default.
- W2070096735 hasConcept C2781303535 @default.
- W2070096735 hasConcept C42475967 @default.
- W2070096735 hasConcept C55493867 @default.
- W2070096735 hasConcept C71924100 @default.
- W2070096735 hasConcept C80107235 @default.